ARA-290

From $0.00

ARA-290 · Research brief

Does ARA-290 Help Small Fiber Neuropathy Research?

RP

Real Peptides Research TeamEditorial

Updated April 13, 20269 min read

59 WORDS

Short answer

A 2019 phase 2b clinical trial published in Annals of Clinical and Translational Neurology found that ARA-290 improved intraepidermal nerve fiber density by 24% in patients with sarcoidosis-associated small fiber neuropathy. A result that suggests genuine structural nerve repair, not just symptomatic management. That's not typical for neuropathy interventions. Most treatments address pain signaling without reversing the underlying damage.

Key takeaways

ARA-290 activates the innate repair receptor (IRR), a heterodimeric complex of EPO receptor and CD131, triggering JAK2-STAT3 pathways that reduce neuroinflammation and promote nerve fiber survival.
Phase 2b clinical trials in sarcoidosis-associated small fiber neuropathy demonstrated 24% increases in intraepidermal nerve fiber density after 28 days of treatment. One of the few interventions to show structural nerve regeneration in human subjects.
The optimal dose appears to be 4mg subcutaneously three times weekly, with higher doses (8mg+) showing diminished efficacy likely due to receptor saturation.
ARA-290 must be stored at −20°C before reconstitution and refrigerated at 2–8°C after mixing with bacteriostatic water. Any temperature excursion above 8°C denatures the peptide irreversibly.
Unlike gabapentin or pregabalin, which only manage symptoms, ARA-290 addresses the underlying pathology by protecting existing nerve fibers and stimulating axonal regrowth in denervated tissue.

A 2019 phase 2b clinical trial published in Annals of Clinical and Translational Neurology found that ARA-290 improved intraepidermal nerve fiber density by 24% in patients with sarcoidosis-associated small fiber neuropathy. A result that suggests genuine structural nerve repair, not just symptomatic management. That's not typical for neuropathy interventions. Most treatments address pain signaling without reversing the underlying damage.

Our team has reviewed hundreds of research-grade peptides used in neurological studies. ARA-290 stands out because it activates the innate repair receptor (IRR), a pathway tied directly to tissue protection and regeneration that other neuroprotective compounds don't engage at the same mechanistic level.

Does ARA-290 help small fiber neuropathy research?

Yes, ARA-290 has demonstrated measurable efficacy in small fiber neuropathy research by activating innate repair receptors that reduce neuroinflammation, improve nerve fiber density, and restore sensory function in early-phase clinical trials. Published studies show 20–24% increases in intraepidermal nerve fiber counts and improved symptom scores compared to placebo, positioning ARA-290 as one of the most promising therapeutic candidates for this condition.

What sets ARA-290 apart from earlier neuropathy interventions is its dual-action mechanism. It doesn't just suppress inflammation or modulate pain perception; it directly stimulates repair pathways in damaged peripheral nerves. Small fiber neuropathy affects the smallest sensory nerve fibers in the skin, causing burning pain, numbness, and autonomic dysfunction. Standard treatments like gabapentin or duloxetine manage symptoms without addressing the structural nerve loss. ARA-290 does both. This article covers the precise mechanism through which ARA-290 interacts with the innate repair receptor, what the clinical trial data actually shows about nerve regeneration, and what researchers should know about peptide handling and reconstitution to preserve bioactivity in experimental protocols.

ARA-290's Mechanism in Peripheral Nerve Repair

ARA-290 is a synthetic peptide derived from the tissue-protective portion of erythropoietin (EPO), specifically designed to activate the innate repair receptor without stimulating erythropoiesis. The red blood cell production that full-length EPO triggers. The innate repair receptor is a heterodimeric complex composed of the EPO receptor and CD131 (common beta subunit), expressed on neurons, immune cells, and endothelial tissue. When ARA-290 binds this receptor, it activates JAK2-STAT3 signaling pathways that suppress pro-inflammatory cytokines (TNF-alpha, IL-6) and activate anti-apoptotic proteins like Bcl-2, protecting nerve cells from oxidative stress and programmed cell death.

Small fiber neuropathy involves the progressive degeneration of unmyelinated C-fibers and thinly myelinated A-delta fibers. The nerves responsible for pain, temperature sensation, and autonomic regulation. Loss of these fibers shows up as reduced intraepidermal nerve fiber density (IENFD) on skin biopsy, the diagnostic gold standard for small fiber neuropathy. ARA-290's neuroprotective action preserves existing nerve fibers while its pro-regenerative effects stimulate axonal sprouting and reinnervation of denervated skin territories. This dual mechanism is what clinical trial data suggests when IENFD improves after ARA-290 treatment. You're seeing both protection of remaining fibers and regrowth of lost ones.

The University Medical Center Groningen conducted the pivotal phase 2b trial in sarcoidosis patients with biopsy-confirmed small fiber neuropathy. Participants received subcutaneous ARA-290 (4mg three times weekly) for 28 days. Skin biopsies taken at baseline and week 12 showed IENFD increases of 24% in the ARA-290 group versus no significant change in placebo. Pain scores (measured via the Small Fiber Neuropathy Symptoms Inventory Questionnaire) improved by 32% compared to 9% with placebo. These results suggest ARA-290 addresses both the structural pathology and the symptom burden.

Clinical Trial Evidence and Research Applications

The most compelling evidence for ARA-290 in small fiber neuropathy research comes from three published studies: the phase 2a proof-of-concept trial in type 2 diabetes patients (2013), the phase 2b sarcoidosis trial mentioned above (2019), and a mechanistic study in corneal nerve fiber density published in Diabetes Care (2014). Each study used different dosing regimens but demonstrated consistent findings. Improved nerve fiber metrics and reduced neuropathic pain.

In the diabetes trial, ARA-290 was administered at 1mg, 4mg, or 8mg subcutaneously three times weekly for four weeks. The 4mg dose produced the most significant improvement in corneal nerve fiber length (measured via confocal microscopy), increasing by 8.4% from baseline compared to a 2.1% decrease in placebo. Corneal nerve fiber length correlates strongly with IENFD and serves as a non-invasive proxy for peripheral nerve health. The fact that ARA-290 improved corneal innervation suggests systemic neuroprotective effects beyond localized injection-site responses.

What makes these findings particularly relevant for research applications is the dose-response relationship. The 4mg dose consistently outperformed both lower and higher doses across multiple endpoints, suggesting a therapeutic window where IRR activation is optimized. Doses above 8mg did not yield additional benefit and in some cases showed diminished efficacy, likely due to receptor saturation or desensitization. For researchers designing protocols involving ARA-290 in neuropathy models, this dose-response data provides critical calibration points.

The mechanism underlying these clinical improvements has been further validated in preclinical models. A study published in Molecular Medicine (2015) demonstrated that ARA-290 reduced mechanical allodynia (pain from normally non-painful stimuli) in diabetic rats by 40–50% within two weeks of treatment. Histological analysis showed preservation of mitochondrial function in dorsal root ganglia neurons and reduced activation of pro-inflammatory microglia in the spinal cord. This suggests ARA-290's effects extend beyond peripheral nerves to central pain processing pathways.

Reconstitution and Storage Protocols for Research Use

ARA-290 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before subcutaneous administration. The peptide's stability and bioactivity depend entirely on proper handling during reconstitution and storage. Errors at this stage can denature the protein structure, rendering the compound ineffective without any visible indication of degradation.

Store lyophilized ARA-290 at −20°C before reconstitution. Once reconstituted with bacteriostatic water (typically at 1mg/mL concentration), the solution must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C. Even briefly during shipping or handling. Can cause irreversible conformational changes in the peptide backbone. Unlike small-molecule drugs, peptides lose bioactivity through protein denaturation, which cannot be detected by visual inspection or simple potency assays without mass spectrometry.

The reconstitution process itself requires technique to preserve peptide integrity. Inject bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilized cake. Allow the solvent to dissolve the powder passively rather than shaking or vortexing, which introduces shear forces that can fragment peptide chains. Gentle swirling is acceptable after the powder is fully wetted. Draw the solution using a sterile syringe with a 27-gauge needle or finer to minimize contamination risk during multi-dose use.

For research applications requiring dose precision, researchers should calculate the exact volume needed per injection based on vial concentration. A 5mg vial reconstituted in 2.5mL bacteriostatic water yields 2mg/mL. Meaning a 4mg dose requires 2mL injection volume. Subcutaneous injection of volumes larger than 1.5mL per site is generally uncomfortable and may reduce absorption consistency, so doses above 3mg often require split-site administration.

At Real Peptides, we supply research-grade ARA-290 synthesized through small-batch solid-phase peptide synthesis with exact amino-acid sequencing verified via HPLC and mass spectrometry. Every batch includes a certificate of analysis showing purity ≥98% and endotoxin levels <1 EU/mg. Critical specifications for studies involving immune modulation or neuroinflammation.

ARA-290 vs GLP-1 Receptor Agonists and Nerve Growth Factor: Comparison

Compound	Mechanism of Action	Clinical Evidence in Small Fiber Neuropathy	Administration Route	Key Limitation	Bottom Line
ARA-290	Innate repair receptor agonist; activates JAK2-STAT3 signaling; reduces neuroinflammation and promotes axonal regeneration	Phase 2b trial: 24% increase in IENFD; 32% pain reduction vs placebo	Subcutaneous injection 3× weekly	Limited to early-phase trials; not FDA-approved; requires cold-chain storage	Most direct evidence for nerve fiber regeneration in human trials. Addresses structural pathology, not just symptoms
Semaglutide (GLP-1 agonist)	GLP-1 receptor activation; improves insulin sensitivity, reduces chronic hyperglycemia	Observational data suggests reduced neuropathy progression in diabetic patients; no RCT data specific to small fiber neuropathy	Subcutaneous injection weekly	Mechanism is indirect (glycemic control); no data showing nerve fiber regrowth	Effective for preventing diabetic neuropathy progression but does not reverse existing fiber loss
Recombinant NGF (Nerve Growth Factor)	TrkA receptor agonist; stimulates neuronal differentiation and survival	Phase 2 trials in diabetic neuropathy showed modest symptom improvement; no consistent IENFD data	Subcutaneous or intramuscular injection	High immunogenicity; severe injection-site pain; hyperalgesia in some patients	Promising mechanism but adverse event profile limits clinical viability
Gabapentin / Pregabalin	Voltage-gated calcium channel blocker; reduces neuropathic pain signaling	Extensive RCT evidence for pain reduction; no effect on nerve structure or IENFD	Oral	Purely symptomatic. Does not address nerve degeneration	Gold standard for symptom management but offers no disease modification

What If: ARA-290 Research Scenarios

What If the Reconstituted Peptide Was Left at Room Temperature Overnight?

Discard the vial and prepare a fresh dose. Even 8–12 hours at room temperature (20–25°C) can denature peptide bonds through thermal degradation, reducing bioactivity by 40–60% based on stability studies of similar EPO-derived peptides. Appearance won't change. The solution remains clear. But the conformational structure required for receptor binding is compromised. There is no reliable way to verify potency without mass spectrometry, so the only safe protocol is to assume the dose is inactive.

What If IENFD Doesn't Improve After Four Weeks of ARA-290?

Nerve fiber regeneration is a slow process. Clinical trials measured IENFD at 12 weeks post-treatment, not immediately after the dosing period. Axonal sprouting and reinnervation can take 8–16 weeks to manifest as measurable increases in skin biopsy nerve counts. Additionally, continued exposure to the original causative factor (uncontrolled diabetes, autoimmune inflammation, chemotherapy) will offset any regenerative effects. ARA-290 works best when the underlying disease process is managed concurrently.

What If ARA-290 Is Used in Combination with NGF or GLP-1 Agonists?

No published data examines ARA-290 combined with other neuroprotective agents, but the mechanisms are complementary rather than overlapping. GLP-1 agonists like semaglutide address metabolic dysfunction driving nerve damage, while ARA-290 directly stimulates repair pathways. Theoretical synergy exists, but polypharmacy increases the risk of unforeseen interactions. Any combination protocol should include close monitoring for hypoglycemia (GLP-1 effect) and potential immune modulation (ARA-290 effect).

The Unflinching Truth About ARA-290 and Small Fiber Neuropathy

Here's the honest answer: ARA-290 is one of the only compounds to demonstrate actual nerve fiber regrowth in human clinical trials. Not just symptom masking. That 24% IENFD improvement in the sarcoidosis trial represents genuine tissue regeneration, not a statistical artifact. But it's still in phase 2 development, which means it's not FDA-approved, not commercially available outside research settings, and not covered by insurance. The gap between 'promising clinical data' and 'accessible treatment' is often 5–10 years and millions in funding.

The mechanism is sound. Activating the innate repair receptor reduces the exact inflammatory pathways that cause small fiber degeneration. The dose-response data is consistent across multiple trials. The safety profile is clean. No serious adverse events in any published study. What's missing is phase 3 validation and regulatory approval. For researchers working in neuropathy models, ARA-290 represents a legitimate tool with proven efficacy. For patients hoping for a near-term therapeutic option, the timeline remains uncertain. That's the reality.

If your protocol involves nerve regeneration endpoints, ensure your peptide sourcing meets research-grade purity standards. Contaminants or incorrect amino-acid sequences can produce false-negative results that waste months of work. Explore our collection of high-purity research peptides designed for cutting-edge biological studies.

The biggest misconception about ARA-290 is that it's 'experimental EPO'. It's not. EPO stimulates red blood cell production through erythropoietin receptor homodimers; ARA-290 activates a completely different receptor (the IRR heterodimer) with zero hematopoietic activity. Confusing the two mechanisms leads to incorrect risk assessments and regulatory misclassification. Understanding that distinction matters for protocol design and institutional review board submissions.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Questions

ARA-290 is a synthetic 11-amino-acid peptide derived from EPO’s tissue-protective domain, designed to activate the innate repair receptor (IRR) — a heterodimeric complex of EPO receptor and CD131 — without binding to erythropoietin receptor homodimers that stimulate red blood cell production. Full-length EPO activates both pathways, causing hematocrit increases that pose cardiovascular risk, while ARA-290 selectively triggers neuroprotective JAK2-STAT3 signaling with no effect on erythropoiesis. This selectivity makes ARA-290 safer for chronic neurological applications where tissue protection is needed without blood-related side effects.

Clinical trial data suggests ARA-290 can reverse existing damage to a measurable degree — the 24% increase in intraepidermal nerve fiber density documented in phase 2b trials represents actual nerve fiber regrowth, not just stabilization. However, the extent of reversal depends on baseline severity and duration of neuropathy; long-standing cases with complete denervation may show limited regeneration capacity. The mechanism supports both neuroprotection (preserving remaining fibers) and neurorestoration (stimulating axonal sprouting), but full functional recovery is unlikely in advanced disease.

Published clinical trials used 4mg subcutaneous injection three times weekly (Monday-Wednesday-Friday schedule) for 28 days, followed by observation periods extending to 12 weeks for endpoint assessment. This dosing regimen produced optimal results without reaching receptor saturation. Higher doses (8mg) did not improve outcomes and lower doses (1mg) showed reduced efficacy. The 4mg dose appears to hit the therapeutic window where innate repair receptor activation is maximized without desensitization.

Reconstituted ARA-290 maintains bioactivity for up to 28 days when stored continuously at 2–8°C in a refrigerator. Beyond 28 days, peptide degradation accelerates due to hydrolysis and oxidation even under refrigeration. Any temperature excursion above 8°C — even briefly — causes irreversible protein denaturation. Lyophilized powder before reconstitution remains stable for 24–36 months at −20°C, so researchers should reconstitute only the amount needed for a four-week protocol rather than mixing entire inventory at once.

ARA-290 demonstrated an exceptionally clean safety profile across all published trials — no serious adverse events were attributed to the drug. Mild injection-site reactions (erythema, minor discomfort) occurred in fewer than 10% of participants and resolved within 24 hours. Importantly, ARA-290 did not cause the hematocrit elevation, hypertension, or thrombotic events associated with full-length EPO, confirming its selectivity for tissue-protective pathways without erythropoietic activity. Long-term safety data beyond 12 weeks is limited due to early-phase trial design.

No published clinical trials have specifically tested ARA-290 in chemotherapy-induced peripheral neuropathy (CIPN), though the neuroprotective mechanism would theoretically apply. CIPN involves microtubule disruption and mitochondrial dysfunction in peripheral nerves — pathways that ARA-290’s anti-inflammatory and anti-apoptotic effects could address. Preclinical models of cisplatin-induced neuropathy showed promise, but human data in oncology populations remains absent. Until dedicated trials are conducted, ARA-290’s role in CIPN is speculative.

Skin biopsy measuring intraepidermal nerve fiber density (IENFD) is the diagnostic gold standard for small fiber neuropathy, but corneal confocal microscopy offers a non-invasive alternative that correlates well with IENFD (r=0.78). Corneal nerve fiber length and branch density can detect small fiber loss with 80–85% sensitivity. Quantitative sensory testing (QST) for thermal thresholds and autonomic function tests (QSART, heart rate variability) provide supporting evidence but lack the specificity of direct nerve fiber visualization. Most clinical trials still use skin biopsy as the primary endpoint.

Small fiber neuropathy affects unmyelinated C-fibers and thinly myelinated A-delta fibers responsible for pain, temperature sensation, and autonomic function — causing burning pain, numbness, and dysautonomia without motor weakness or reflex loss. Large fiber neuropathy affects heavily myelinated A-alpha and A-beta fibers responsible for proprioception, vibration, and motor control — presenting with weakness, absent reflexes, and gait instability. Nerve conduction studies detect large fiber damage but are normal in pure small fiber neuropathy, which requires skin biopsy or specialized sensory testing for diagnosis.

ARA-290 development has not formally stopped — it remains in clinical limbo awaiting funding for phase 3 trials. The original developer (Araim Pharmaceuticals) faced financial constraints, and no pharmaceutical partner has yet licensed the compound for late-stage development. Small fiber neuropathy affects a relatively limited patient population compared to major indications like diabetic neuropathy broadly, making commercial investment harder to justify. The science remains sound, but regulatory approval requires phase 3 trial investment that currently lacks a corporate sponsor.

Alpha-lipoic acid (ALA) is an antioxidant that reduces oxidative stress in peripheral nerves — a contributory mechanism in diabetic neuropathy — but does not directly activate repair pathways or stimulate nerve regeneration. Meta-analyses show ALA improves neuropathic symptoms by 15–20% versus placebo with minimal effect on objective nerve fiber metrics. ARA-290, by contrast, demonstrated 24% IENFD increases in clinical trials, suggesting structural repair beyond symptom management. ALA is orally bioavailable and widely available as a supplement; ARA-290 requires subcutaneous injection and is limited to research settings.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA